Correction: Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria (Genetics in Medicine, (2017), 19, 10, (1105-1117), 10.1038/gim.2017.37);Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria

Genetics in Medicine

Volumn 19, Issue 10, 2017, Pages 1105-1117

  Nykamp, Keith ^a   Anderson, Michael ^a   Powers, Martin ^a   Garcia, John ^a   Herrera, Blanca ^a   Ho, Yuan Yuan ^a   Kobayashi, Yuya ^a   Patil, Nila ^a   Thusberg, Janita ^a   Westbrook, Marjorie ^a   Topper, Scott ^a  

^a Clinical Molecular Geneticist and Cytogeneticist Invitae Corportation   (United States)

Author keywords

ACMG laboratory guideline; clinical genetic testing; clinical interpretation; variant classification; variant interpretation

Indexed keywords

MESSENGER RNA;

ARTICLE; BREAST CANCER; CELL ADHESION; CELL MOTILITY; EXOME; EXON; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; JAG1 GENE; MOLECULAR GENETICS; MYH7 GENE; NONSENSE MEDIATED MRNA DECAY; PHENOTYPE; PRACTICE GUIDELINE; PROTEIN BINDING; PROTEIN FUNCTION; RNA STRUCTURE; STOMACH CANCER; TUMOR SUPPRESSOR GENE; ZYGOSITY; DNA SEQUENCE; GENETIC SCREENING; GENETIC VARIATION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; PROCEDURES; SOFTWARE; STANDARDS;

GENETIC TESTING; GENETIC VARIATION; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SEQUENCE ANALYSIS, DNA; SOFTWARE;

EID: 85029554726     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/s41436-019-0624-9     Document Type: Erratum

References (50)

1. National Institutes of Health, Secretary's Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: recommendations of the SACGT, 2000. http://osp.od.nih.gov/sites/default/files/oversight- report.pdf. Accessed 26 October 2016
2. Rehm HL, Berg JS, Brooks LD, et al. ClinGen-the clinical genome resource. N Engl J Med 2015;372:2235-2242
3. Garcia J, Tahiliani J, Johnson NM, et al. Clinical genetic testing for the cardiomyopathies and arrhythmias: A systematic framework for establishing clinical validity and addressing genotypic and phenotypic heterogeneity. Front Cardiovasc Med 2016;3:20
4. Kumar D. From evidence-based medicine to genomic medicine. Genomic Med 2007;1:95-104
5. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424
6. Amendola LM, Jarvik GP, Leo MC, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet 2016;98:1067-1076
7. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42:D980-D985
8. Wen J, Brogna S. Nonsense-mediated mRNA decay. Biochem Soc Trans 2008;36:514-516
9. Kaurah P, Huntsman DG. Hereditary diffuse gastric cancer. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 2002
10. Corso G, Roviello F, Paredes J, et al. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur J Surg Oncol 2007;33:1061-1067
11. Mateus AR, Simoes-Correia J, Figueiredo J, et al. E-cadherin mutations and cell motility: A genotype-phenotype correlation. Exp Cell Res 2009;315:1393-1402
12. Roviello F, Corso G, Pedrazzani C, et al. Hereditary diffuse gastric cancer and E-cadherin: description of the first germline mutation in an Italian family. Eur J Surg Oncol 2007;33:448-451
13. Stoetzel C, Laurier V, Faivre L, et al. BBS8 is rarely mutated in a cohort of 128 Bardet-Biedl syndrome families. J Hum Genet 2006;51:81-84
14. Parry D, Peters G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 1996;16:3844-3852
15. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;338:879-887
16. McNally EM, de Sá Moreira E, Duggan DJ, et al. Caveolin-3 in muscular dystrophy. Hum Mol Genet 1998;7:871-877
17. Jovanovic B, Egyhazi S, Eskandarpour M, et al. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol 2010;130:618-620
18. Wadt KA, Aoude LG, Krogh L, et al. Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition. PLoS One 2015;10:e0122662
19. Harland M, Meloni R, Gruis N, et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 1997;6:2061-2067
20. Walker GJ, Hussussian CJ, Flores JF, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995;4:1845-1852
21. Eliason MJ, Larson AA, Florell SR, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 2006;126:660-666
22. Flores JF, Pollock PM, Walker GJ, et al. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 1997;15:2999-3005
23. Wang Q, Chen S, Chen Q, et al. The common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel. J Med Genet 2004;41:e66
24. Duzkale H, Shen J, McLaughlin H, et al. A systematic approach to assessing the clinical significance of genetic variants. Clin Genet 2013;84:453-463
25. Kobayashi Y, Yang S, Nykamp K, et al. Pathogenic variant burden in the ExAC database: An empirical approach to evaluating population data for clinical variant interpretation. Genome Med 2017;9:13
26. Varon R, Demuth I, Digweed M. Nijmegen breakage syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 1999
27. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 2008;124:31-42
28. Zimmerman BT. Understanding Breast Cancer Genetics. University Press of Mississippi: Jackson, MS, 2004
29. Saleh M, Kamath BM, Chitayat D. Alagille syndrome: clinical perspectives. Appl Clin Genet 2016;9:75-82
30. Ahn KJ, Yoon JK, Kim GB, et al. Alagille syndrome and a JAG1 mutation: 41 cases of experience at a single center. Korean J Pediatr 2015;58:392-397
31. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med 2013;15:972-977
32. Dunn KE, Caleshu C, Cirino AL, et al. A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management. Circ Cardiovasc Genet 2013;6:118-131
33. Nicholls M. The 2014 ESC guidelines on the diagnosis and management of hypertrophic cardiomyopathy have been published. Eur Heart J 2014;35:2849-2850
34. Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2014;89:727-737
35. Lalani SR, Hefner MA, Belmont JW, Davenport SLH. CHARGE syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 2006
36. Mehta PA, Tolar J. Fanconi anemia. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 2002
37. Petrucelli N, Daly MB, Pal T. BRCA1 and BRCA2 hereditary breast and ovarian cancer. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 1998
38. Jacquet A, Guiochon-Mantel A, Noel LH, et al. Alagille syndrome in adult patients: it is never too late. Am J Kidney Dis 2007;49:705-709
39. Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003;80:207-215
40. Andreasen C, Nielsen JB, Refsgaard L, et al. New population-based exome data are questioning the pathogenicity of previously cardiomyopathyassociated genetic variants. Eur J Hum Genet 2013;21:918-928
41. Tournier I, Vezain M, Martins A, et al. A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects. Hum Mutat 2008;29:1412-1424
42. Viel A, Genuardi M, Capozzi E, et al. Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer. Genes Chromosomes Cancer 1997;18:8-18
43. Genuardi M, Carrara S, Anti M, et al. Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2. Eur J Hum Genet 1999;7: 778-782
44. Wanat JJ, Singh N, Alani E. The effect of genetic background on the function of Saccharomyces cerevisiae mlh1 alleles that correspond to HNPCC missense mutations. Hum Mol Genet 2007;16:445-452
45. Trojan J, Zeuzem S, Randolph A, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology 2002;122:211-219
46. Hinrichsen I, Brieger A, Trojan J, et al. Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis. Clin Cancer Res 2013;19:2432-2441
47. Kondo E, Suzuki H, Horii A, et al. A yeast two-hybrid assay provides a simple way to evaluate the vast majority of hMLH1 germ-line mutations. Cancer Res 2003;63:3302-3308
48. Shimodaira H, Filosi N, Shibata H, et al. Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae. Nat Genet 1998;19: 384-389
49. Tang H, Thomas PD. Tools for predicting the functional impact of nonsynonymous genetic variation. Genetics 2016;203:635-647
50. Grimm DG, Azencott CA, Aicheler F, et al. The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity. Hum Mutat 2015;36:513-523.